arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

Grace Therapeutics, Inc.

GRCE
$2.13 ▼ -0.03 (-1.39%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
37
Health
Weak
Bearish
auto_awesome

Analytical Summary

Grace Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $36.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -33.0%
FCF / Share $-0.19
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-15.79M
↓ -369.7%
FCF / Share Free cash flow per share
$-0.19
↓ -64.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
25
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 31 quarters